Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005110-200207000-00004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.
Clin Lymphoma Myeloma Leuk
February 2025
Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
Background: In the phase 3 CANDOR trial (NCT03158688), daratumumab added to carfilzomib and dexamethasone (KdD) significantly prolonged progression-free survival relative to carfilzomib and dexamethasone (Kd) alone in previously treated patients with relapsed/refractory multiple myeloma (RRMM).
Materials And Methods: We present a post hoc analysis of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-item module (EORTC QLQ-C30) and EORTC QLQ Myeloma 20-item module (EORTC QLQ-MY20) patient-reported outcome (PRO) measures from the CANDOR trial.
Results: Median (range) duration of observation for PROs was 18.
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Nat Commun
March 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance.
View Article and Find Full Text PDFSpatial and single-cell transcriptomic analysis reveals fibroblasts dependent immune environment in colorectal cancer.
Biofactors
March 2025
Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Colorectal cancer (CRC) exhibits a complex tumor microenvironment with significant cellular heterogeneity, particularly involving cancer-associated fibroblasts that influence tumor behavior and metastasis. This study integrated single-cell RNA sequencing and spatial transcriptomics to dissect fibroblast heterogeneity in CRC. Data processing employed Seurat for quality control, principal component analysis for dimensionality reduction, and t-Distributed Stochastic Neighbor Embedding for visualization.
View Article and Find Full Text PDFLaughter and Life in the Geri-a-FLOAT Community: A Rising Tide Lifts all Boats, Brains, and Hearts.
J Am Geriatr Soc
March 2025
Section of Geriatrics, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial.
Nat Med
March 2025
Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Early data from the DYNAMIC study of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy (ACT) versus standard approach met its primary outcome demonstrating reduced ACT use without compromising 2-year recurrence-free survival (RFS) for stage II colon cancer. We report here other prespecified analyses of overall survival, ctDNA clearance and ctDNA level. At a median follow-up of 59.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!